Prior Authorization Delays: How Pharmacy Liens Solve Them

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 26, 2026 | 8 min read

Insurance prior authorization creates treatment gaps averaging 2-3 weeks that harm PI patients and weaken cases. Learn how pharmacy liens bypass PA requirements and why treatment continuity strengthens settlement demands.

Prior Authorization Delays: How Pharmacy Liens Solve Them

Insurance prior authorization (PA) — the requirement that a physician obtain insurer approval before a prescribed medication can be dispensed — creates treatment delays averaging two to three weeks that directly harm personal injury patients and simultaneously weaken their legal cases. A pharmacy lien through LienScripts bypasses the prior authorization process entirely, ensuring patients receive their prescribed medications on the day the physician writes the prescription while generating the uninterrupted dispensing records that strengthen the demand package.

• Prior authorization delays average 2-3 weeks according to an AMA survey, with some extending to 30+ days (AMA 2023 Prior Authorization Physician Survey)
• During PA delays, patients go without prescribed medications, creating treatment gaps that defense counsel exploits
• Common PI medications requiring PA include branded muscle relaxants, neuropathic agents (pregabalin), COX-2 inhibitors (celecoxib), sleep medications, and compound creams
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report showing continuous, uninterrupted medication access without PA-related gaps
• Pharmacy liens operate outside the insurance framework, eliminating PA as a barrier to treatment

The Prior Authorization Problem in PI Cases

Prior authorization was designed as a cost-containment tool — insurers require physicians to justify certain prescriptions before agreeing to cover them. For personal injury patients, this process creates a dangerous conflict: the treating physician has determined a medication is medically necessary, but the insurer delays or denies access based on formulary preferences and cost considerations.

According to James Wong, PharmD, founder of LienScripts, "Prior authorization is an insurance cost-control mechanism that has nothing to do with clinical appropriateness. When a PI patient's physician prescribes pregabalin for neuropathic pain and the insurer requires a PA, that delay is not medical review — it is administrative gatekeeping that leaves the patient in pain."

[!KEY] Prior authorization delays create treatment gaps that directly harm PI patients and simultaneously weaken their cases — the gap appears in pharmacy records as a period without medication fills, which defense counsel characterizes as evidence that the medication was not truly needed.

How PA Delays Harm the Legal Case

Treatment Gap Exploitation

The most damaging effect of PA delays on the legal case is the treatment gap they create. When a patient goes two to three weeks without a prescribed medication because of PA processing, the pharmacy record shows no fills during that period. Defense counsel routinely argues:

• "If the patient really needed the medication, they would have found a way to get it"
• "The gap shows the medication was not medically necessary"
• "The patient was doing fine without the medication during the delay"

These arguments are disingenuous — the patient was not "doing fine," they were suffering without medication because of an administrative process — but the gap in pharmacy records provides the factual basis for the argument.

Suboptimal Substitution

During PA delays, physicians often prescribe an inferior alternative that does not require PA. For example, when pregabalin requires PA, the physician may prescribe gabapentin instead. While gabapentin can be effective, the prescriber had clinical reasons for choosing pregabalin — better bioavailability, more predictable dosing, or a specific pharmacokinetic profile suited to the patient.

This forced substitution creates a confusing medication history that defense counsel uses: "The patient switched medications multiple times, suggesting the treating physician was uncertain about the diagnosis."

Delayed Treatment Initiation

For some medications, particularly specialty drugs and biologics, the PA process can take 30+ days. During this period, the patient's condition may worsen, requiring additional treatment that would not have been necessary if the original medication had been dispensed promptly.

[!TIP] When reviewing a client's pharmacy records, look for gaps between the prescription date (on the medical record) and the first fill date (on the pharmacy record). A gap of more than a few days often indicates a PA delay. Document this in the demand narrative as an insurance-created treatment barrier, not a voluntary treatment interruption.

Medications Commonly Subject to PA in PI Cases

Neuropathic Agents

• Pregabalin (Lyrica) — nearly always requires PA; insurers prefer generic gabapentin
• Branded duloxetine formulations — PA required when generics are available

COX-2 Inhibitors

• Celecoxib (brand Celebrex) — PA required when generic celecoxib is available at some plans; brand-only formulations always require PA

Sleep Medications

• Lemborexant (Dayvigo) — PA required as a newer, branded agent
• Daridorexant (Quviviq) — PA required; no generic equivalent
• Eszopiclone or zolpidem ER — PA sometimes required based on formulary tier

Muscle Relaxants

• Branded tizanidine formulations — PA for brand when generic is available
• Baclofen at higher doses — some plans require PA for doses above standard thresholds

Specialty and Compound Medications

• Compound topical creams — almost universally denied by insurance; PA process often results in denial
• Biologic medications — extensive PA requirements with step therapy mandates

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The medications that most frequently require prior authorization are often the ones PI patients need most urgently — neuropathic agents for nerve pain, specialty sleep medications for post-traumatic insomnia, and compound formulations for complex pain. The PA process creates exactly the treatment gaps that undermine the case."

How Pharmacy Liens Bypass Prior Authorization

A pharmacy lien operates entirely outside the insurance framework. When a physician prescribes a medication for a patient enrolled in LienScripts' pharmacy lien program:

1. The prescription is sent directly to the LienScripts pharmacy network
2. The medication is dispensed at zero upfront cost — no insurance billing, no PA required
3. The cost is documented as part of the pharmacy lien against the settlement proceeds
4. The patient receives the medication the same day or next day

No PA submission. No waiting period. No insurance denial. No forced substitution.

[!KEY] A pharmacy lien bypasses the entire prior authorization process because the medication is not billed to insurance. The physician prescribes, the pharmacy dispenses, and the cost is documented on the lien — creating an uninterrupted treatment record that defense counsel cannot attack as gap-laden or inconsistent.

The Documentation Advantage

Beyond eliminating treatment gaps, pharmacy lien dispensing creates a cleaner, more compelling medication record:

Consistent Fill Patterns

When medications are dispensed on lien without PA delays, the pharmacy record shows regular, consistent fill dates that document ongoing medical need. There are no unexplained gaps, no forced substitutions, and no periods of under-treatment.

Physician-Directed Treatment

The physician prescribes exactly what they determine is clinically appropriate, without insurance formulary constraints forcing substitutions. The medication record reflects pure clinical judgment rather than a compromise between clinical need and insurance coverage.

Complete Documentation

Every dispensing event through LienScripts is documented with the precision required for legal proceedings — date, medication, quantity, prescriber, and NDC code. The MERIT report synthesizes this into a clinical narrative.

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages.

Adjuster Objections and Responses

"The medication was available through insurance if the PA was completed." Counter: PA delays averaged two to three weeks during which the patient suffered without treatment. The physician determined the medication was needed immediately. A pharmacy lien ensures the patient receives treatment on the physician's timeline, not the insurer's.

"The pharmacy lien bypassed cost controls." Counter: The pharmacy lien bypassed administrative delays, not clinical oversight. The prescribing physician made the clinical determination of medical necessity. The PA process is a cost-control mechanism, not a clinical review — the insurer is not the treating physician.

"The patient should have used their insurance." Counter: Using insurance would have created a multi-week treatment gap while PA was processed, during which the patient's condition would have worsened. The pharmacy lien ensured immediate, uninterrupted treatment.

[!TIP] If you have clients who started with insurance and experienced PA delays before enrolling in a pharmacy lien, document the contrast. Show the treatment gap under insurance followed by continuous treatment on lien — this comparison powerfully illustrates why the lien was medically necessary.

Related Resources

• Insurance Denial and Medication Access
• Treatment Gaps and Medication Access
• Zero Upfront Cost Prescriptions
• How LienScripts Works